Dianthus Therapeutics, Inc. /DE/ Quarterly Debt-to-equity in % from Q1 2019 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Dianthus Therapeutics, Inc. /DE/ quarterly Debt-to-equity history and growth rate from Q1 2019 to Q3 2024.
  • Dianthus Therapeutics, Inc. /DE/ Debt-to-equity for the quarter ending September 30, 2024 was 3.83 %, a 97.5% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 3.83 -151 -97.5% Sep 30, 2024
Q2 2024 4.19 +35.3 Jun 30, 2024
Q1 2024 5.84 +66.2 Mar 31, 2024
Q4 2023 14.7 +117 Dec 31, 2023
Q3 2023 154 +281 Sep 30, 2023
Q2 2023 -31.1 -116 -137% Jun 30, 2023
Q1 2023 -60.3 -83.7 -358% Mar 31, 2023
Q4 2022 -103 -114 -1043% Dec 31, 2022
Q3 2022 -126 -139 -1070% Sep 30, 2022
Q2 2022 85.1 +71.3 +519% Jun 30, 2022
Q1 2022 23.4 +8.91 +61.6% Mar 31, 2022
Q4 2021 10.9 -4.46 -29.1% Dec 31, 2021
Q3 2021 13 +0.95 +7.88% Sep 30, 2021
Q2 2021 13.7 +1.8 +15.1% Jun 30, 2021
Q1 2021 14.5 +2.79 +23.9% Mar 31, 2021
Q4 2020 15.4 +4.71 +44.2% Dec 31, 2020
Q3 2020 12.1 +2.89 +31.5% Sep 30, 2020
Q2 2020 11.9 +3.18 +36.3% Jun 30, 2020
Q1 2020 11.7 +4.03 +52.7% Mar 31, 2020
Q4 2019 10.6 Dec 31, 2019
Q3 2019 9.17 Sep 30, 2019
Q2 2019 8.76 Jun 30, 2019
Q1 2019 7.65 Mar 31, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.